EDARADD and cancer: Thus, we examined whether there was a difference in the methylation profiles of seven immune response gene promoters: EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12, between cancer samples and controls.